Articles tagged with Drug Targets
Researchers found that FDA-approved drugs Betaxolol and Pravastatin can increase muscle strength in mouse models of DMD by stimulating utrophin production. This approach could lead to novel therapies for Duchenne muscular dystrophy, potentially offering advantages over traditional gene replacement methods.
A new study confirms that ethambutol, a key TB drug, targets specific proteins in the bacteria. Researchers used cryogenic electron microscopy and x-ray imaging to show how the drug binds to and inactivates these proteins, producing crucial components of the TB cell wall.
A USC-led team of scientists has discovered the precise shape of the melanocortin 4 receptor, a key player in human metabolism. The findings could lead to more effective therapies for obesity and other metabolic diseases, which affect millions worldwide.
New research on the structure of HIV has revealed a promising novel drug target that can prevent further infection by targeting the genetic code. This discovery offers hope for more effective treatments and potentially fewer side effects for HIV patients.
A case series of lung cancer patients taking osimertinib (Tagrisso) revealed a rare twist in the right side of their colon, cecal volvulus. Doctors using this drug with EGFR+ non-small cell lung cancer patients should watch for these cases alongside more expected side effects.
Scientists at UT Southwestern Medical Center have discovered a protein called Meis1 that works with Hoxb13 to stop heart cell division, but deleting both genes can help heart cells regenerate. This finding could lead to new treatments for heart failure and other conditions.
A recent study published in Nature Cancer has revealed a critical pathway that regulates the production of PD-L1, a protein used by cancer cells to evade the immune system. By targeting this pathway, researchers hope to develop more effective cancer immunotherapies.
Researchers discovered that T cells respond differently to immune signals based on their 'training', revealing a continuum of memory experience. This spectrum affects how fast a cell can respond and what signals it can respond to.
A new study identifies key genes driving fibrolamellar carcinoma, a rare and deadly liver cancer. Researchers developed a cell model to test combination therapy strategies, including inhibitors of genes SLC16A14 and CA12, which showed promising results in killing tumor cells.
Researchers at OIST Graduate University have discovered the structure of adhesive pili in Porphyromonas gingivalis, a major bacterial pathogen causing gum disease. The study sheds light on how these pili assemble and provides insights into combating diseases associated with P. gingivalis.
Researchers at Hokkaido University discovered a lipid gradient in tears that helps form and maintain the tear film's inner liquid layer and outer lipid layer. This finding could lead to new treatments for dry eye disease by targeting the lipid layer.
Researchers found that a key TB antibiotic can't irreversibly inhibit an enzyme, instead allowing it to function again through hydrolysis. This discovery could lead to the development of improved versions of the drug and new treatments for antibiotic-resistant bacteria.
The new drug Ru-Pt combines cisplatin, phenylbutyrate, and a PDT drug into one compound, increasing the chances of killing all cancer cells. It shows significant efficiency in killing cancer cells and has a ten times higher efficiency for drug-resistant cell lines than single reagents.
Researchers found that Aspergillus molds attack the lung's epithelial cells, causing a leaky barrier and triggering an overreaction to future mold exposure. The TRPV4-calcium pathway plays a key role in this response, suggesting new avenues for preventing asthma.
Researchers uncovered how approximately 80% of screened cytotoxic compounds rely on solute carriers for activity, providing insights into drug mechanisms and SLC biology. The study also highlights the need for systematic surveys of transporter-drug relationships to develop more effective precision therapies.
A study published in Nature Communications reveals that microglia can both protect and damage the blood-brain barrier, depending on the level of systemic inflammation. The researchers used fluorescent labeling and two-photon imaging to study the interactions between microglia and the blood-brain barrier.
Researchers found 31 broad-spectrum antiviral agents that could be used to treat and prevent COVID-19. These existing drugs have already been shown to be safe for human use and may offer a faster alternative to developing new treatments.
A breakthrough discovery by Trinity College Dublin researchers identifies Caspase-11 as a key driver of allergic inflammation in asthma. This finding holds great promise for developing new therapeutic options to treat the debilitating disease.
Dr. Silvia Fossati, a Temple University Health System researcher, has been awarded a $500,000 grant to develop an Alzheimer's-specific version of a carbonic anhydrase inhibitor drug family. The goal is to target mitochondrial dysfunction, amyloid protein build-up, and inflammation in the brain, which are hallmarks of Alzheimer's disease.
The discovery of CRISPR-Cas9 systems has revolutionized pharmaceutical research by allowing for industrial-scale gene editing and functional genomic screening. This enables the identification of new biological targets for precision medicines and the exploration of mechanisms of drug resistance and sensitivity ahead of clinical trials.
The Kong group will investigate how neurons and muscle cells communicate, with the goal of understanding how to reactivate neurons in injured muscle. They will also develop a drug delivery system to target tau proteins responsible for Alzheimer's disease.
The new guidelines, if implemented, would lead to a substantial financial burden on health systems due to the high cost of PCSK9 inhibitors. Around 50% of patients with a recent heart attack would be eligible for these expensive drugs, which could increase treatment costs by over 4,500 euros annually.
A team of NUS researchers identified a novel protein S1P2 that can protect nerve cells from damage and pain when activated with a drug-like compound. This discovery holds promise for the prevention and treatment of chemotherapy-induced neuropathy, as well as other forms of neuropathy.
Target-based ecological compensation provides a framework for linking compensatory requirements to biodiversity targets, ensuring no net loss of species habitats. This approach resolves uncertainty and promotes better outcomes for the planet and people.
A novel injectable drug, NOV004, is being developed by Novosteo Inc. to heal broken bones faster and strengthen weak bones. The treatment concentrates at the fracture site while reducing exposure to the rest of the body, potentially reducing mortality rates among older adults.
Researchers discovered EphA2 protein plays a crucial role in cerebral malaria by disrupting blood-brain barrier, leading to leaky brain and deadly symptoms. Blocking EphA2 with drugs may prevent disease in humans, offering hope for alleviating this condition.
A recent study published in Blood Advances eliminates BCL-W as a potential therapeutic target for B cell lymphomas. The research team used gene editing technology and demonstrated that human B cell lymphoma cell lines can survive without BCL-W, contradicting earlier speculation about its role in cancer survival.
Scientists have made an important discovery that could lead to more effective treatments for people living with multiple sclerosis (MS). The study found that drugs targeting the IL-17 molecule may not need to get across the blood-brain-barrier to be effective in treating MS.
A newly identified compound, C1, is a covalent gamma-secretase inhibitor that blocks the production of amyloids by inhibiting the enzyme's activity on the amyloid precursor protein. This approach avoids traditional enzyme inhibitors' severe side effects and shows promise for treating Alzheimer's disease.
A research team has discovered a possible target for new sleeping sickness drugs using an X-ray laser. The scientists decoded the structure of a key enzyme in the parasite Trypanosoma brucei, which could lead to a specific drug that kills the parasite.
A collaboration between Rutgers University and Scripps Research has led to the discovery of a small molecule that reduces α-synuclein protein levels, potentially slowing or stopping Parkinson's disease progression. This finding offers hope for early-stage patients and may be applicable to other neurodegenerative diseases like Alzheimer's.
A comprehensive roadmap has been established to evaluate and implement ivermectin as a complementary vector control tool against malaria. The roadmap aims to decrease malaria transmission by targeting the vector population, bypassing challenges of insecticide resistance and residual transmission.
Scientists have shed light on the structure and functioning mechanism of CysLT receptors, regulating inflammatory responses associated with allergic disorders. The study identified critical ligand-binding determinants, enabling better understanding of receptor-ligand complexes and potential drug targets.
A new study reveals that certain enzymes, known as cathepsins, not only promote diseases like cancer but also cannibalize and deactivate each other. By modeling these interactions, researchers hope to develop more effective inhibitors with fewer side effects.
Researchers mapped protein-drug interactions in rat organs and blood, revealing potential drug targets. The study represents a significant advancement for translational research, allowing direct monitoring of biological changes in an organ.
Researchers at UC Riverside are targeting cancer-causing genes Mcl-1 and Bfl-1 for novel therapies in melanoma and lung cancers. They aim to develop potent agents that can help tackle chemotherapy-resistant cancers.
Researchers scanned the brains of young adults with ADHD while taking methylphenidate to study its effect on the brain's reward system. The results showed that methylphenidate increased activity in the ventral striatum in response to rewards, suggesting a possible mechanism for improving focus and behavior in individuals with ADHD.
Researchers found an average increase in stem cell count of 68% with minimal side effects, reducing 'stressed' cells and improving conditions for pregnancy. The treatment aims to prevent miscarriage by normalizing the womb lining.
Australian researchers have identified a new drug target for preventing the deadliest malaria parasite from spreading infection. The breakthrough involves blocking the export of gametocyte proteins, essential for malaria transmission, using small molecule inhibitors developed at the Walter and Eliza Hall Institute.
Researchers at Karolinska Institutet have developed a new tool that provides more reliable and precise results in identifying protein targets for cancer drugs. The tool uses a database of experimentally determined data to analyze the effects of different drugs on various types of cancer cells.
A new analysis confirms human genomic data can predict success in clinical trials, with genetically supported drug targets twice as likely to be approved. Historically, drugs targeting proteins with amino acid sequence changes linked to the disease have the best chance of approval.
A study published in EMBO Molecular Medicine suggests that blocking the protease MT1-MMP could protect the vasculature in the inflamed gut and reduce severity of colitis. The research found that inhibiting this protease could have potential clinical implications, including identifying biomarkers for mild IBD.
A new study found that Class I drug treatment showed increased rates of AFib reoccurrence in obese patients compared to non-obese patients. The study suggests that obesity hinders the effectiveness of these medications, which could impact ethnic minority populations who are more likely to experience obesity and have poorer outcomes.
Researchers have identified 111,582 gene fusions in eight species, including humans, mice, and cattle. The ChiTaRS database provides a list of over 800 druggable fusions useful for personalized therapy in complex diseases like cancers and Alzheimer's.
Researchers at Cold Spring Harbor Laboratory have developed a new therapy that extends the survival of mice with acute myeloid leukemia by blocking the Salt-Inducible Kinase 3 (SIK3) pathway. The treatment, YKL-05-099, is a first in demonstrating anti-cancer effects of SIK3 inhibition using pharmacological blockade.
Researchers discovered that cells with extra chromosome 21 in DS mice activated a biological circuit that detects stress and tamps down protein production, leading to cognitive impairments. By targeting this stress response, scientists were able to reverse learning and memory deficits in the mouse model.
A Scottish government-funded social prescribing initiative failed to improve patients' health-related quality of life. In a subgroup analysis, those who visited the practitioner three or more times showed improved quality of life, but many non-users did not fully utilize the program.
A research team found that Dasatinib, a leukemia treatment, suppressed glial cell activity and pro-inflammatory cytokine expression, inhibiting encephalitis reactions. The study revealed the efficacy of drug repositioning to treat degenerative brain diseases like Alzheimer's.
Researchers used ultrashort X-ray pulses to study Photosystem I, a large biomolecular system converting sunlight into chemical energy. This breakthrough paves the way for time-resolved studies on electron transfer in photosynthesis, with potential applications in medicine and next-generation solar energy storage.
Researchers identify a potential target for eliminating leukemia stem cells using vitamin K3, which stabilizes the DYRK2 enzyme. This approach could lead to treatment-free remissions and improved patient outcomes.
A new poll finds that half of older Americans have taken leftover antibiotics without guidance, while one in five expect doctors to prescribe them for colds. Despite widespread awareness of antibiotic resistance, many older adults engage in risky practices, highlighting opportunities for education and improved prescribing.
A new healthcare framework aims to improve diagnosis and treatment of age-related diseases by classifying and staging severity. The framework, developed by an international team of experts, includes a comprehensive classification system for aging-related diseases in all organs.
A comprehensive genome sequencing study reveals rare CFTR mutations in Puerto Rican and Dominican patients, driving the disease's progression. This finding underscores the need for diverse clinical trials to develop personalized therapies, as transformative new drugs may not benefit minority populations.
Researchers solved the three-dimensional structure of potassium chloride cotransporter 1 (KCC1) using cryo-electron microscopy. The study's findings provide new insights into the protein's role in regulating cell volume, particularly in the kidneys and brain, and shed light on potential treatments for hereditary epilepsy.
Researchers have identified a new mechanism by which cancer cells become resistant to ferroptosis, a type of cell death. A molecule called FSP1 acts as a lipid antioxidant, rescuing cancer cells from ferroptosis even when they are starved of GPX4.
Researchers at the University of Dundee have discovered an enzyme that could prevent Group A Streptococcus infections by inhibiting a carbohydrate coating on the bacterium's surface. The discovery offers new opportunities for developing antimicrobial drugs with minimal off-target effects.
Researchers found that suppressing neural overactivity extends life span in humans, while excessive activity is linked to shorter life spans. The study suggests a role for the protein REST in modulating neural activity and activating a longevity pathway.
A phase III trial found that olaparib significantly delayed disease progression by about four months compared to enzalutamide and abiraterone, resulting in a 66 per cent greater delay. The study highlighted the importance of genomic testing in prostate cancer patients.
A modern chemotherapy drug is more effective against advanced prostate cancer than a second targeted hormone therapy, with cabazitaxel extending men's lives by an average of 3 months. The study suggests that cancer's lethal ability to develop drug resistance affects treatment response across precision medicines.
Researchers at University of Eastern Finland developed a new approach to improve brain drug delivery by utilizing LAT1. The study showed that prodrugs can be converted into active drugs that utilize LAT1 for cell entry, achieving higher concentrations in target cells.